Article
Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling.
Lung cancer (Amsterdam, Netherlands) - 1 Oct 2020
Madison Russell, Schrock Alexa B, Castellanos Emily, Gregg Jeffrey P, Snider Jeremy, Ali Siraj M, Miller Vincent A, Singal Gaurav, Alexander Brian M, Venstrom Jeffrey M, Chung Jon H
Abstract excerpt
OBJECTIVES: Liquid biopsy and comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) are increasingly used for detection of targetable genomic alterations (GA) in non-small cell lung cancer (NSCLC). To examine the clinical outcomes for patients following CGP using liquid biopsy versus tissue biopsy, receipt of matched targeted therapy post-CGP and associated outcomes were evaluated in the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.